9989 — Shenzhen Hepalink Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- HK$6.97bn
- HK$6.74bn
- CNY5.48bn
Annual income statement for Shenzhen Hepalink Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | CAS | CAS | CAS | CAS | CAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6,365 | 7,159 | 5,446 | 5,281 | 5,479 |
| Cost of Revenue | |||||
| Gross Profit | 1,998 | 2,296 | 945 | 1,748 | 1,706 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 6,139 | 6,331 | 6,307 | 4,540 | 5,071 |
| Operating Profit | 226 | 828 | -862 | 741 | 408 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 222 | 830 | -928 | 726 | 402 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 233 | 715 | -802 | 625 | 343 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 241 | 727 | -783 | 647 | 349 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 241 | 727 | -783 | 647 | 349 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.266 | 0.485 | -0.497 | 0.357 | 0.319 |
| Dividends per Share |